| Dr Ubong Jackson Udoyen, MD | |
|
58 Augusta Dr, Milford, CT 06461-1683 | |
| (803) 269-7381 | |
| Not Available |
| Full Name | Dr Ubong Jackson Udoyen |
|---|---|
| Gender | Male |
| Speciality | Psychiatry |
| Experience | 25 Years |
| Location | 58 Augusta Dr, Milford, Connecticut |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1134369531 | NPI | - | NPPES |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| State Of Connecticut | 8022915677 | 194 |
News Archive
When it comes to changing the way physicians practice, guidelines and educational initiatives alone are not effective. An editorial by James A. Arrighi, M.D., a cardiologist with Rhode Island Hospital, explains the effective methods to change physician behavior and improve compliance to guidelines. The editorial is published online in advance of print of the February 8 edition of the American Heart Association's journal Circulation.
Halo Therapeutics, LLC, a clinical-stage biopharmaceutical company developing novel therapeutics for rare fibrotic diseases, announced today that the TREAT-NMD Advisory Committee on Therapeutics (TACT) has reviewed HT-100, Halo's drug candidate for Duchenne muscular dystrophy (DMD), and believes the compound has potential based on the proposed mechanism.
Two innovative programs designed to improve the availability of emerging medical technologies that can help patients receive more effective, efficient and personalized health care are advanced in a commentary written by a team of scientists and policy experts, including seven from Arizona State University, and published today in Science Translational Medicine.
After a recent University of Illinois study showed that injection of the soy peptide lunasin dramatically reduced colon cancer metastasis in mice, the researchers were eager to see how making lunasin part of the animals' daily diet would affect the spread of the disease.
› Verified 2 days ago
| Entity Name | The Griffin Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1184639973 PECOS PAC ID: 8921901984 Enrollment ID: O20040128000937 |
News Archive
When it comes to changing the way physicians practice, guidelines and educational initiatives alone are not effective. An editorial by James A. Arrighi, M.D., a cardiologist with Rhode Island Hospital, explains the effective methods to change physician behavior and improve compliance to guidelines. The editorial is published online in advance of print of the February 8 edition of the American Heart Association's journal Circulation.
Halo Therapeutics, LLC, a clinical-stage biopharmaceutical company developing novel therapeutics for rare fibrotic diseases, announced today that the TREAT-NMD Advisory Committee on Therapeutics (TACT) has reviewed HT-100, Halo's drug candidate for Duchenne muscular dystrophy (DMD), and believes the compound has potential based on the proposed mechanism.
Two innovative programs designed to improve the availability of emerging medical technologies that can help patients receive more effective, efficient and personalized health care are advanced in a commentary written by a team of scientists and policy experts, including seven from Arizona State University, and published today in Science Translational Medicine.
After a recent University of Illinois study showed that injection of the soy peptide lunasin dramatically reduced colon cancer metastasis in mice, the researchers were eager to see how making lunasin part of the animals' daily diet would affect the spread of the disease.
› Verified 2 days ago
| Entity Name | State Of Connecticut |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1720013360 PECOS PAC ID: 8022915677 Enrollment ID: O20040319000785 |
News Archive
When it comes to changing the way physicians practice, guidelines and educational initiatives alone are not effective. An editorial by James A. Arrighi, M.D., a cardiologist with Rhode Island Hospital, explains the effective methods to change physician behavior and improve compliance to guidelines. The editorial is published online in advance of print of the February 8 edition of the American Heart Association's journal Circulation.
Halo Therapeutics, LLC, a clinical-stage biopharmaceutical company developing novel therapeutics for rare fibrotic diseases, announced today that the TREAT-NMD Advisory Committee on Therapeutics (TACT) has reviewed HT-100, Halo's drug candidate for Duchenne muscular dystrophy (DMD), and believes the compound has potential based on the proposed mechanism.
Two innovative programs designed to improve the availability of emerging medical technologies that can help patients receive more effective, efficient and personalized health care are advanced in a commentary written by a team of scientists and policy experts, including seven from Arizona State University, and published today in Science Translational Medicine.
After a recent University of Illinois study showed that injection of the soy peptide lunasin dramatically reduced colon cancer metastasis in mice, the researchers were eager to see how making lunasin part of the animals' daily diet would affect the spread of the disease.
› Verified 2 days ago
| Entity Name | Mobvilvax, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1124610704 PECOS PAC ID: 0042625022 Enrollment ID: O20221220000933 |
News Archive
When it comes to changing the way physicians practice, guidelines and educational initiatives alone are not effective. An editorial by James A. Arrighi, M.D., a cardiologist with Rhode Island Hospital, explains the effective methods to change physician behavior and improve compliance to guidelines. The editorial is published online in advance of print of the February 8 edition of the American Heart Association's journal Circulation.
Halo Therapeutics, LLC, a clinical-stage biopharmaceutical company developing novel therapeutics for rare fibrotic diseases, announced today that the TREAT-NMD Advisory Committee on Therapeutics (TACT) has reviewed HT-100, Halo's drug candidate for Duchenne muscular dystrophy (DMD), and believes the compound has potential based on the proposed mechanism.
Two innovative programs designed to improve the availability of emerging medical technologies that can help patients receive more effective, efficient and personalized health care are advanced in a commentary written by a team of scientists and policy experts, including seven from Arizona State University, and published today in Science Translational Medicine.
After a recent University of Illinois study showed that injection of the soy peptide lunasin dramatically reduced colon cancer metastasis in mice, the researchers were eager to see how making lunasin part of the animals' daily diet would affect the spread of the disease.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Ubong Jackson Udoyen, MD 58 Augusta Dr, Milford, CT 06461-1683 Ph: (803) 269-7381 | Dr Ubong Jackson Udoyen, MD 58 Augusta Dr, Milford, CT 06461-1683 Ph: (803) 269-7381 |
News Archive
When it comes to changing the way physicians practice, guidelines and educational initiatives alone are not effective. An editorial by James A. Arrighi, M.D., a cardiologist with Rhode Island Hospital, explains the effective methods to change physician behavior and improve compliance to guidelines. The editorial is published online in advance of print of the February 8 edition of the American Heart Association's journal Circulation.
Halo Therapeutics, LLC, a clinical-stage biopharmaceutical company developing novel therapeutics for rare fibrotic diseases, announced today that the TREAT-NMD Advisory Committee on Therapeutics (TACT) has reviewed HT-100, Halo's drug candidate for Duchenne muscular dystrophy (DMD), and believes the compound has potential based on the proposed mechanism.
Two innovative programs designed to improve the availability of emerging medical technologies that can help patients receive more effective, efficient and personalized health care are advanced in a commentary written by a team of scientists and policy experts, including seven from Arizona State University, and published today in Science Translational Medicine.
After a recent University of Illinois study showed that injection of the soy peptide lunasin dramatically reduced colon cancer metastasis in mice, the researchers were eager to see how making lunasin part of the animals' daily diet would affect the spread of the disease.
› Verified 2 days ago
Christine Elaine Desmond, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 949 Bridgeport Ave, Milford, CT 06460 Phone: 203-878-6365 | |
Dr. Howard Feldman, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 16 Rock Rd, Milford, CT 06460 Phone: 203-874-0895 | |
Terrell David Holloway, MD Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 472 Wheelers Farms Rd Ste 306, Milford, CT 06461 Phone: 203-701-9737 | |
Donna W Klimowicz, M.D. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 949 Bridgeport Ave, Milford, CT 06460 Phone: 203-878-6365 | |
Dr. Burton G. Austen, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 75 New Haven Avenue, Milford, CT 06460 Phone: 212-614-1011 Fax: 203-389-9896 | |
Lisa Harding, M.D. Psychiatry & Neurology Medicare: May Accept Medicare Assignments Practice Location: 472 Wheelers Farms Rd Ste 306, Milford, CT 06461 Phone: 563-676-8923 Fax: 859-545-5013 |